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Epilepsy is one of the most prevalent neurological disorders, and mesial temporal lobe 
epilepsy (MTLE) is the most pharmacoresistant form of epilepsy. About 30% of these 
patients are not controlled by antiepileptic drugs (AED) therapy, being necessary the 
use of surgical intervention to control the seizures, although only less than 10% of 
patients are eligible for surgery. Current AED only treat symptoms with no reduction or 
even cure of epilepsy. The high prevalence and percentage of refractory epilepsy have 
motivated extensive research concerning new regulatory systems of neurotransmitters 
or neuromodulators, in order to reduce this pathology.   
Adenosine (ADO) modulates neuronal activity, being considered an endogenous 
anticonvulsant. ADO levels increase dramatically during seizures leading to activation 
of inhibitory A1 receptors, decreasing excitatory neurotransmission contributing in this 
way to the cessation of seizures and to the post-ictal refractoriness. Being ADO an 
ubiquitary molecule, its administration per se would lead to numerous adverse effects, 
mainly cardiovascular???????? ??????????and inactivation mechanisms in the brain are 
spotlighted by researchers aiming new therapeutic targets, with focal adenosine 
augmentation in the hippocampus as one as the most feasible approaches in the near 
future. Implants applied in the hippocampus of experimental models regulate or release 
ADO in situ. These implants contained release-control ADO polymers, histaminals cells 
manipulated to release ADO or "anti-sense" genes against the adk gene of 
dysregulated adenosine kinase (ADK), which controls the extracellular levels of ADO. 
The ketogenic diet, used mainly in the control of refractory epilepsy in children, has 
also been studied. 
The domain of these mechanisms will allow the development of completely innovative 
conceptual strategies for the treatment and possible cure of a syndrome as complex as 
epilepsy, in a broader sense that goes beyond mere symptomatic suppression. 
 










A epilepsia é uma das doenças neurológicas mais prevalentes, e a epilepsia do lobo 
mesial temporal (MTLE) a mais frequente das epilepsias resistentes a fármacos. Cerca 
de 30% dos pacientes com MTLE não são controlados por fármacos anti-epilépticos 
(AED), sendo a cirúrgica a única alternativa para controlar as convulsões, em que 
apenas 10% dos pacientes são elegíveis. A terapia actual com AED apenas trata os 
sintomas, sem redução ou possível cura da epilepsia. A prevalência e percentagem 
elevadas de doentes com epilepsia farmacorresistente justificam a vasta investigação 
sobre os sistemas reguladores e/ou neuromoduladores da hiperexcitabilidade 
neuronial.  
A adenosina (ADO) modula a atividade neuronial, sendo considerada um 
anticonvulsivante endógeno. Os níveis da ADO aumentam dramaticamente durante as 
convulsões. A activação dos receptores inibitórios A1 da ADO, reduz a 
hiperexcitabilidade, controla a crise e assegura a refractoriedade pós-convulsiva. 
Sendo a ADO uma molécula ubiquitária, a administração sistémica conduziria a 
inúmeros efeitos adversos, nomeadamente cardiovasculares. 
O domínio dos mecanismos de formação e inactivação da ADO no cérebro está na 
base da intensa investigação visando novos alvos terapêuticos. O aumento da 
adenosina focal no hipocampo é uma das abordagens mais viáveis num futuro 
próximo: implantes aplicados no hipocampo de modelos experimentais regulam ou 
libertam ADO in situ. Esses implantes podem conter polímeros de libertação 
controlada de ADO, células histaminais manipuladas que libertam ADO ou genes "anti-
sense" contra o gene adk da enzima adenosina cinase (ADK) desregulada, que 
controla os níveis extracelulares de ADO. A dieta cetogénica, usada sobretudo no 
controlo de epilepsia refractária em crianças, tem sido também estudada. 
Estratégias conceptuais inovadoras que vão além da supressão dos sintomomas, são 
a esperança para o tratamento de uma das doenças neurológicas mais prevalentes no 
mundo. 
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Abbreviation List  
ADK ? Adenosine Kinase  
Adk gene ? Adenosine Kinase gene 
ADO ? Adenosine 
AMP ? ????????????-monophosphate  
AR ? Adenosine Receptor          
ATP ? ????????????-triphosphate  
BDNF ? Brain-derived Neurotrophic Factor  
CNS ? Central Nervous System  
COX - Ciclooxygenase  
COXIBE ? Selective COX2-inhibitor 
GABA ? ?-Aminobutyric Acid  
HS - Hippocampal Sclerosis  
KA ? Kainic Acid 
KATP ? inwardly rectifying potassium channels 
MTLE - Mesial Temporal Lobe Epilepsy 
mTOR - Mammalian Target of Rapamycin Protein 
NADH ? Nicotinamide Adenine Dinucleotide  
RNA - Ribonucleic Acid  
SE ? Status Epilepticus 









Epilepsy is a chronic neurological disease, the most common worldwide. According to 
the World Health Organization (WHO, 2009), about 50 million people are affected by 
this disease. 
Partial epilepsies occurring in adulthood are most likely to be mesial temporal lobe 
epilepsies (MTLE), the most frequent form of pharmacoresistant epilepsy (Theodore, 
1991). This neurological disorder cannot be controlled with medication in 30% of cases. 
Therefore, surgical intervention is necessary, in order to control the seizures (Spencer 
et al., 1984). 
Adenosine (ADO) is an extracellular signaling molecule, able to coordinate 
???????????? ??? ??????????????????????? ?????????????????on and repair (Linden, 2005). In 
the nervous system ADO also exerts a rather specific neuromodulatory role, controlling 
synaptic transmission and synaptic plasticity (Gomes et al., 2011), as well as 
coordinating neuronal networks (Sperlagh and Vizi, 2011). ????????????????????????????
allows considering ADO as a therapeutic target in the management of neurologic 
disorders. However, part of the ????? role seems to be related to the patophysiology 
of epilepsy because ADO acts as an endogenous anticonvulsant (Boison, 2006). 
Subsequently impaired adenosinergic modulation is thought to be involved in the 
?????????????? ????????? ?????????????????? ????????????? ??? ??????? ???? ??????????????
eventually, allow researchers to develop entirely new conceptual strategies, in order 















This present review focuses on the relevance of the ADO-mediated mechanisms in the 
pathophysiology of epilepsy, in particular on MTLE. It aims to report the most relevant 
therapeutic strategies developed in recent years, and which will provide pioneering 
drugs in the treatment of epilepsy.  
Therefore, a short overview of epileptogenesis, epilepsy and MTLE will be made. The 
role of ADO in brain function and its clinical implications in epilepsy will be highlighted. 
Describing the various approaches designed to increase ADO brain levels will be the 























As proposed by the International League Against Epilepsy (ILAE) and the International 
Bureau for Epilepsy (IBE) in 2005, epilepsy is defined as a brain disorder characterized 
by an enduring predisposition to generate epileptic seizures and by the neurobiologic, 
cognitive, psychological, and social consequences of this condition (Fisher et al, 2005). 
Traditionally, the diagnosis of epilepsy requires the occurrence of at least two 
unprovoked seizures. Some clinicians also diagnose epilepsy when one unprovoked 
seizure occurs in the setting of a predisposing cause (such as a focal cortical injury) or 
if a generalized interictal discharge occurs suggestive of a genetic predisposition.  
Seizures are the manifestation of abnormal hypersynchronous or hyperexcitable 
discharges of cortical neurons. The clinical signs or symptoms of seizures depend on 
the location of the epileptic discharges in the cerebral cortex and the extent and pattern 
of the propagation of the epileptic discharge in the brain. The probability of having at 
least one epileptic seizure in lifetime is about 9% and the probability of being 
diagnosed as epileptic is almost 3%, while the prevalence of active epilepsy is only 
about 0.8% (Pugliatti et al., 2007).   
In a substantial number of cases, the cause of epilepsy remains unknown. Identified 
causes tend to vary with patient age: Inherited syndromes, congenital brain 
malformations, infection, and head trauma are primary causes in children; head trauma 
is the most common known cause in young adults; strokes, tumors, and head trauma 
become more frequent in middle age adults; stroke is the main cause in the elderly, 
along with Alzheimer disease and other degenerative conditions. 
Anti-epileptic drugs (AEDs) are the frontline treatment for epilepsy (Wiebe and Jette, 
2012). There are over twenty AEDs in clinical use, including phenytoin, sodium 
valproate and carbamazepine, and newer generation drugs such as levetiracetam and 
lacosamide. The introduction of newer generation AEDs has provided a wider range of 
treatment options that can reduce potential side effects and allow better tailoring of 
therapies to an individual?? specific syndrome. However, the proportion of patients with 
pharmacoresistant epilepsy has changed relatively little, remaining at ~30% (Wiebe 
and Jette, 2012).  Existing AEDs target a relatively small number of proteins. These 
include: enhancement of inhibitory (GABAergic) transmission; reduction of excitatory 
(glutamatergic) neurotransmission; modulation of neurotransmitter release and 
targeting voltage-gated ion channels (MacDonald and Rogawski, 2008).  Patients with 
poorly-controlled seizures suffer additional reductions in quality of life, severe 
limitations on work and personal activities, and are at increased risk of neurological 
deficits, accidents and death (Pugliatti et al., 2007).  




Mesial Temporal Lobe Epilepsy  
Mesial Temporal Lobe Epilepsy (MTLE), the most common form of pharmacoresistant 
epilepsy (Wieser, 2004), is often associated with previous injuries, including trauma, 
status epilepticus (SE), febrile seizures, and infection (Kharatishvili and Pitkanen, 2010; 
Yang et al., 2010).  
Typically, a standard course of events leads to epileptic status. After the initial insult, a 
latency period of 5?10 years occurs without any symptoms or complications (Wieser, 
2004; Boison, 2008). The latency period ends when the patient begins to suffer from 
spontaneous seizures. At the beggining of spontaneous seizure activity, seizures are 
often controllable with medication. This period is known as the silent period. As the 
disease progresses, patients commonly develop intractable symptoms that cannot be 
managed with the current antiepileptic drugs (Wieser, 2004). The latency period 
associated with epileptogenesis is thought to involve structural and biochemical 
changes resulting in spontaneous seizures. These changes, presumably, are initiated 
by the primary agression and occur over an extended time course (Sharma et al., 
2007). 
 A plethora of changes have been observed in epileptic tissue. Among which, 
astrogliosis (astroglial scar), neuronal death and aberrant mossy ?ber sprouting are 
observed both in animal models (e.g. Pitkanen et al., 2009; Hayashi et al., 2011; Zheng 
et al., 2011) and in resected human tissue (e.g. de Lanerolle et al., 2003; Bae et al., 
2010; Yang et al., 2010). Although the underlying biochemical pathways remain 
unclear, the first structural changes are caused by the primary insult (e.g. Sloviter, 
1996; Sharma et al., 2007). Other authors have proposed that said modifications 
continue to accumulate together with disease progression (Pitkanen and Sutula, 2002; 
Wieser, 2004; Yang et al., 2010).  
Upregulation of in?ammatory indicators was observed (Crespel et al., 2002; Yang et 
al., 2010; Ravizza et al., 2011) with an increase of proin?ammatory cytokines, namely: 
l-calpain, interleukin (IL)-1b, IL-6, and transforming growth factor (TGF)-b1 in resected 
human anterior temporal lobe specimens (Feng et al., 2011). Supporting the ???????????
in?ammatory hypothesis even further, downstream cyclooxygenase-2 (COX-2) 
inhibition in epileptic rats, by selective COX-2 inhibitors (COXIBE??? (Jung et al., 2006; 
Polascheck et al., 2010; Holtman et al., 2009) is found to reduce seizure initiation, 
severity, and frequency while preserving neurons. The in?ammatory hypotheses should 




be treated with caution because although brain inflammation during childhood often 
precedes adult epilepsy, adult-onset epilepsy may emerge when no in?ammatory event 
happened in childhood (Ravizza et al., 2011).  
Morphological Changes 
Neuronal Degeneration  
Neuronal degeneration was one of the ?rst recognized hallmarks of MTLE. Resected 
hippocampi from MTLE patients have decreased size and a rubber-like stiffness. Slices 
of these hippocampus observed on the microscope have a reduction of the number of 
neurons preferentially in CA1, CA3, and the hilus (CA4), whereas CA2 and the dentate 
nucleus seemed to be spared (de Lanerolle et al., 2003). Extrahippocampal neuron 
loss has also been observed in MTLE in the entorhinal cortex, pyriform cortex, and 
amygdala (Ben-Ari and Dudek., 2010). The role and mechanism of neuronal 
degeneration in MTLE remain unclear.  
 
Figure 1: Nissl-stained coronal sections of hippocampi from representative cases 
Density and distribution of neurons are similar in autopsy and non-MTLE hippocampi. By contrast, the MTLE 
hippocampus shows severe loss of neurons, particularly in areas CA1 and CA3 and the dentate hilus. Magnification is 
the same for all sections (adapted from Eid et al., 2004) 
Gliosis 
Gliosis is the common denominator of various neurological diseases including human 
and animal epileptic tissue (Pitkanen and Sutula, 2002; Sharma et al., 2007; Thom, 
2014). Chronic astroglial activation increases in?ammatory cytokine production, 
potentiates excessive synaptic activity and induces a migration to the epileptic focus, 
resulting in sclerosis. Whether these effects are responsive to MTLE or inducers of 
MTLE has yet to be answered. 
 




Mossy Fiber Sprouting 
Mossy ?ber sprouting is characterized by dentate granule cell axons forming synapses 
with cells in the granule cell layer and inner molecular layer rather than in the CA3 
???????????????????orn (Sharma et al., 2007). Wich changes deriving from seizures 
conduct to sprouting are currently unknown. Gliosis and the release of growth factors, 
cytokines, and adhesion molecules from activated astrocytes and microglia (Yang et 
al., 2010) probably are in the basis of the sprouting phenomenon. Sprouting is 
progressive and is brought on by recurrent seizures (Pitkanen and Sutula, 2002). 
Hiperexcitation hypothesis purport that dentate granule cells become hyperexcitable as 
a result of recurrent sprouting since mossy ?bers are glutamatergic axons and 
establish excitatory circuits within the inner molecular layer (Sharma et al., 2007). 
Conversely, other investigators believe that mossy ?ber sprouting serves to reform 
inhibitory circuits that are lost during the initial damage of neurons, supported by the 
fact that mossy ?bers synapse primarily on inhibitory interneurons in control animals 
(Gorter et al., 2001). Additionally, it has been noted that mossy ?ber sprouting occurs 
secondary to neuron loss (Jankowsky and Patterson, 2001). Observations of 
reinnervation of dormant basket cells by mossy ?bers and of collateral sprouts from 
interneurons forming inhibitory feedback to granule cells also rienforces the 
antiepileptogenic hypothesis (Ben-Ari and Dudek, 2010). Recently, Sharma and 
colleagues (2007) noted that aberrant sprouting precedes seizure onset in rats 
exposed to kainic acid (KA). This observation does not clarify the question of the role of 
mossy ?bers, unfortunately, because whether the sprouting itself leads to seizure 
production or the inability to sprout further leads to seizure production is unclear. 
Clarifying the role that mossy ?bers play in epileptogenesis is an important step in 






Figure 2. Axonal sprouting in Hippocampal sclerosis (HS)/temporal lobe epilepsy (TLE).  
Mossy fibre sprouting identified with Timm staining in human hippocampal sclerosis (HS) (A-C). In (A) the black silver 
granules are mainly confined to the subgranular zone and significant sprouting into the molecular layer (arrow) is not 
observed. In (B) there is focal sprouting in the molecular layer (arrow) and in (C) marked sprouting is shown with a 
dense band of zinc positive granules in the molecular layer (adapted from Thom M 2014). 




Potencial Targets for Seizure Control 
The need for new AEDs is a widely-recognized goal for the improved treatment of 
epilepsy (Baulac and Pitkanen, 2008). Innovative treatments may either be targeted to 
epileptogenesis, the morphological and functional changes leading to epilepsy after an 
initial brain insult, or to ictogenesis, the processes involved in initiation, propagation 
and amplification of seizures in the epileptic brain. Possible features of new AED 
targets include proteins with more subtle influence on excitatory neurotransmission to 
avoid the common side effects of many AEDs. Anti-neuroinflammatory (Venazzi et al., 
2011) or neuroprotective properties (Acharya et al., 2008) could also yield disease-
modifying effects that would mitigate the underlying pathology. 
Adenosine ? A Retaliatory Metabolite 
The ribonucleoside adenosine (ADO) has early evolutionary origins and likely played a 
role in prebiotic evolution (Oro and Kimball, 1961). Importantly, ADO is not only part of 
the energy molecule Adenosine Triphosphate (ATP) but also of Ribonucleic Acid 
(RNA), the nucleic acid thought to be at the origin of life (Lahav, 1993; Dworkin et al., 
2003; Robertson and Joyce, 2012). While ATP re?ects the energy pool in the 
environment, RNA re?ects the metabolic activities of a cell. Thus, ADO assumes a 
central place between energy availability and metabolic demands and has therefore 
been termed a retaliatory metabolite (Newby et al., 1985). The early evolutionary 
principle to conserve energy was likely a rise in ADO as a consequence to ATP 
depletion and to use the increase in ADO as a negative feedback regulator to attenuate 
all cellular activities that consume energy. This early evolutionary principle is 
omnipresent in all living systems and in every human organ. In the brain, epileptic 
seizures cause a rapid drop in energy, which results in the generation of ADO levels 
that can exceed the basal level more than 40 times (During and Spencer, 1992); it is 
this rise of ADO that acts as endogenous terminator of seizures and which is 
responsible for the postictal refractoriness that normally follows a seizure (Lado and 
Moshe, 2008). Seizure suppression by ADO depends on the activation of G protein 
coupled adenosine A1 receptors (Fredholm et al, 2005a); however, new evidence 
suggests that ADO retains important ADO receptor-independent regulatory functions, 
which are based on interactions with mitochondrial bioenergetics, interference with 
enzyme reactions, and epigenetic functions. Thereby ADO assumes a unique role as 
homeostatic network regulator. 
 




Adenosine Receptor-Dependent Pathways 
A number of ????? actions are mediated by a group of speci?c receptors, G protein-
linked transmembrane proteins of the P1 family, distinguished from the P2 ATP 
receptor family. Four members of the P1 family have been cloned in mammals: 
adenosine subtype 1 (A1R), 2A (A2AR), 2B (A2BR) and 3 (A3R) receptors (Fredholm 
et al, 2011). Homologous genes have been found in numerous other animal groups 
(Sazanov et al, 2000; Petersen et al., 2003; Dolezelova et al., 2007; Boehmler et al., 
2009; Malik and Buck, 2010). These receptors have biochemical speci?city as each act 
through a particular set of G proteins to in?uence second messengers: A1R and A3R 
activation inhibit the second messenger cAMP production, whereas A2AR and A2BR 
activation increase cAMP (Fredholm et al., 2011). Other second messengers such as 
diacylglycerol, inositol triphosphate, and Ca2+ are also modulated. Each receptor 
presents a distinct pharmacology, and each has a particular distribution in tissues and 
cell types. A1Rs are expressed mosthighly in brain, whereas A2BRs and A3Rs have 
their highest expression in the periphery (Dixon et al., 1996). Within the brain, A1Rs 
are widespread with particularly high levels in the limbic system, whereas A2ARs are 
expressed mostly in the basal ganglia (Dixon et al., 1996). ADO can have powerful 
receptor-mediated effects on synaptic transmission in the brain (Fredholm et al., 2011). 
Presynaptic A1Rs inhibit synaptic release of most, if not all, neurotransmitters, with an 
apparently greater effect on excitatory transmission. Thus, if ADO levels are raised 
suf?ciently, synaptic transmission can be blocked altogether. On the postsynaptic side, 
A1Rs hyperpolarize membranes by opening inwardly rectifying K+ channels. These 
combined A1R effects play a major role in the ef?cacious anticonvulsant effect of ADO 
and A1R agonists (Boison, 2007). The effect of A2ARs on network excitability is less 
clear, and more anatomically restricted, but if seizures re?ect brain network imbalance, 
then one seizure model suggests that A1Rs and A2ARs may cooperate to promote 
homeostasis (De Sarro et al., 1999). 
Mitochondrial Bioenergetics 
Mitochondria generate ATP via oxidative phosphorylation, and this is the main process 
of energy generation. Regarding the relationship between ADO and ATP, intracellular 
ADO is dephosphorylated from Ade?????????-monophosphate (AMP) and is converted 
back to AMP via adenosine kinase (ADK). The ADO-AMP cycle is linked to ADP and 
ATP through ADK. Thus, ADO is linked tightly to energy metabolism. Whereas 
mitochondrial uncouplers decrease ATP and increase ADO, mitochondrial enhancers 
which boost ATP levels also appear to increase ADO. Therefore, improving 




mitochondrial bioenergetics has the potential to offer dual bene?ts of improving 
metabolic dysfunction and restoring ADO homeostasis (Boison et al., 2013). 
The intracellular concentration of ATP is nearly 50 times higher than that of AMP (Arch 
and Newsholme, 1978) and about 10,000 times higher than that of ADO (Pazzagli et 
al., 1995; Delaney and Geiger, 1996) and minor decreases in intracellular ATP leads to 
a large rise of intracellular ADO level. Thus, various excitatory stimuli cause decreased 
brain energy and a subsequent increase in ADO (Shepel et al., 2005). As a retaliatory 
metabolite ADO is thought to be one of the keylinks between neuronal network 
homeostasis and mitochondrial bioenergetics with both adenosine receptor-dependent 
and independent pathways. 
Ketogenic Diet 
In the early 1920s, the ketogenic diet was first introduced to treat patients,mainly 
children, with refractory epilepsy. However, with the introduction of diphenylhydantoin 
in the following decade the diet faded from the clinical arsenal. In the 1990s its clinical 
interest was renewed and since then more palatable diet variants were developed. 
The diet is high in fat and low in carbohydrate and protein, providing sufficient protein 
for growth but insufficient amounts of carbohydrates for all the metabolic needs 
(Freeman et al., 2006). During high rates of fatty acid oxidation, in mitochondria, large 
amounts of acetyl-CoA are generated, leading to the synthesis of three ketone bodies - 
hydroxybutyrate, acetoacetate, and acetone. Ketone bodies pass into circulation, 
causing serum levels to rise severalfold, and then are utilized as an energy source in 
extrahepatic tissues, including the brain. The ketone bodies are converted to acetyl-
CoA by D-hydroxybutyrate dehydrogenase, acetoacetate-succinyl-CoA transferase, 
and acetoacetyl-CoAthiolase and then enter the Krebs cycle within brain mitochondria, 
leading to ATP production (Masino and Geiger, 2008).  
Ketone bodies have an important role on seizure protection and the proposed 
mechanisms for this occurrence are:  
a) glutamate transport into synaptic vesicles (vesicular glutamate transporter 
VGLUT2), is inhibited by the ketone body acetoacetate (Juge et al, 2010), 
decreasing glutamate release; 
b)  increased production of the inhibitory neurotransmitter ?-Aminobutyric acid 
(GABA) by glutamate recycling via glutamine; reduction of brain derived 
neurotrophic factor (BDNF) and its receptor TrkB expression, both being 




implicated in epileptogenesis, by a decline in the cytosolic reduced nicotinamide 
adenine dinucleotide (NADH) (Garriga-Canut et al., 2006);  
c) ATP activation of nearby ATP-sensitive potassium (KATP) channels (Haller et al., 
2001; Tanner et al., 2011), generating hyperpolarizing K+ currents (Ashcroft and 
Gribble, 1998);  
d) Increased extracellular ADO levels by mitochondrial ATP and consequent 
reduction of neuronal excitability by activating pre and postsynaptic A1Rs.  
The increase on extracellular ADO levels is critical to the therapeutic success of the 
ketogenic diet (Masino and Geiger, 2008). 
DNA Methylation Hypothesis 
Epigenome modifications which include changes in DNA methylation, histone tail 
modi?cations, and incorporation of histone variants are mechanisms by which network 
homeostasis can be dramatically altered and consequently alter the entire gene 
expression pro?le of a tissue. There are a number of epilepsy-associated neurological 
diseases that are directly attributed to primary genetic mutations and result in 
secondary deregulation of the epigenome (Kobow and Blumcke, 2011). Gene 
promoters from MTLE patients have altered DNA methylation patterns and decreased 
DNA methyltransferase gene expression (Kobow et al., 2009; Zhu et al., 2012). This 
hypermethylated state forms the basis of the methylation hypothesis of 
epileptogenesis, suggesting that seizures by themselves can induce epigenetic 
chromatin modi?cations and thereby aggravate the epileptogenic condition (Kobow and 
Blumcke, 2011). Hypermethylation of DNA can be triggered by a variety of 
mechanisms, however, the mechanisms underlying the gradual increase in DNA 
methylation during the course of epileptogenesis are not well characterized and subject 
of speculation (Kobow and Blumcke, 2012). The epigenetic drift hypothesis suggests 
that a gradual shift in the ratio of active DNA demethylation and de novo methylation, 
triggered by an injury and modi?ed by environmental and intrinsic factors leads to 
increased DNA methylation, altered gene expression, and an altered (e.g., seizure) 
phenotype (Feil and Fraga, 2011). 
Peripheral changes in the transmethylation pathway are conserved within the brain. It 
was recently found that hippocampal ADO levels regulate the global state of DNA 
methylation by shifting the equilibrium constant of the transmethylation pathway either 
increasing (high ADK and low ADO) or decreasing (low ADK and high ADO) 
methylation. These ADO dependent changes in DNA methylation are receptor-
independent and can be evoked by either a single pharmacological bolus of ADO (icv 




administration) or in response to endogenous changes in ADK expression or activity 
(Williams-Karnesky et al., 2013).  
As an obligatory endproduct of transmethylation, ADO?? tone non-speci?cally drives the 
transmethylation pathway by regulating substrate availability. Consequently, ??????
tone does not regulate site speci?c DNA methylation, but instead the homeostasis of 
the DNA-methylome.  
Through this mechanism, astrogliosis and associated overexpression of ADK could 
contribute to continued epileptogenesis through maintenance of a hypermethylated 
state of hippocampal DNA (Williams-Karnesky et al., 2013). 
Unbalance of Adenosine Kinase in the Brain 
Astrocytes have the main regulative function on maintenance of extracellular ADO 
levels. The astrocyte-based enzyme ADK phosphorylates adenosine to AMP driving 
the in?ux of ADO into the astrocyte through equilibrative transporters. Injuries to the 
brain such as trauma, stroke or SE trigger an acute surge in ADO, which is 
accompanied by transient downregulation of ADK (Clark et al, 1997; Pignataro et al, 
2008). The initial injury and the associated surge in ADO can trigger several 
mechanisms possibly implicated in epileptogenesis, among which the induction of 
A2AR expression in glial cells appears to play a prominent role. The proliferation of 
astrocytes and thereby the development of astrogliosis is in part regulated by the ratio 
of the different ADO receptors expressed on the astrocyte membrane. The increased 
activation of A2ARs by an injury- associated surge in ADO can increase astrocyte 
proliferation and activation, whereas the blockade of excitatory A2ARs prevents the 
induction of astrogliosis by BDNF, which is a known transactivator of the A2AR 
(Hindley et al., 1994; Brambilla et al., 2003; Rajagopal et al., 2004). ADO de?ciency in 
human epilepsy has directly been identi?ed via the analysis of microdialysis samples. A 
25% reduction of ADO in the epileptogenic versus the contralateral control 










Focal Adenosine Augmentation 
Systemic augmentation of ADO signaling by either A1 receptor agonists or by ADK-
inhibitors effectively suppress seizures in a wide range of epilepsy models including 
those resistant to conventional AEDs (Gouder et al., 2003; McGaraughty et al., 2005; 
Benarroch, 2008). Unfortunately, systemic augmentation of ADO signaling is not a 
therapeutic option due to widespread, mainly cardiovascular, side effects, and due to 
the liver toxicity of ADK disruption (Boison et al., 2002; Fredholm et al., 2005a). 
Therefore, focal ADO augmentation approaches, with the aim to reconstruct ADO 
homeostasis within an epileptogenic brain area, become a therapeutic necessity. Focal 
ADO augmentation to suppress epileptic seizures was ?rst successfully performed in 
rat kindling models of epilepsy using intraventricular implants engineered to release 
ADO (Huber et al., 2001). Importantly, focal ADO augmentation, in contrast to systemic 
ADO augmentation, was not associated with any sedative side effects (Guttinger et al., 
2005). Unfortunately, duration of seizure control (12 days) was limited by a reduced life 
expectancy of the encapsulated cells (Huber et al., 2001). Currently, new approaches 
are being developed to make therapeutic use of ADO augmentation:  
- Silk is a Food and Drug Administration (FDA) approved biocompatible 
biopolymer that can be engineered for controlled focal drug release. 
Infrahippocampal implants of silk which were engineered to release de?ned 
daily doses of up to 1 mg of ADO provided complete control of seizures in the 
kindled rat for the duration of the ADO release (1 mg ADO per day for 10 days) 
(Szybala et al., 2009). Mouse embryonic stem cells and human mesenchymal 
stem cells were also engineered to release ADO from silk implants (Shetty and 
Hattiangady, 2007) 
-  ADO releasing stem cells based on genetic disruption of the endogenous 
adenosine kinase (adk) gene or by expressing a micro RNA (miRNA) directed 
against adk gene via a lentiviral vector (Fedele et al., 2004; Ren et al., 2007) 
potently suppressed kindling epileptogenesis after transplantation into the 
infrahippocampal ?ssure with upregulation of ADK (Li et al., 2007b). Marked 
astrogliosis attenuation, normalization of ADK expression levels and total 
absence of seizures were registrated three weeks later, supporting a novel and 
persistant antiepileptogenic effect of focal ADO delivery. 
 
 





Epilepsy is a neuronal disorder characterized by abnormal and excessive neuronal 
firing where each seizure represents a rapid loss of homeostatic equilibrium, with 
altered energy and molecular gradients, and a corresponding interruption of normal 
behavior and consciousness. Because having a seizure can increase the likelihood of 
future seizures, seizures themselves contribute to epileptogenesis (Boison et al., 
2013).  
Over the past few decades, many studies have sought to identify and treat key 
changes associated with epilepsy and spontaneous seizures. Many morphological and 
biochemical changes identified agravate epilepsy and may steer to a refractory state, 
where no AED therapy is able to control seisures. MTLE is the most frequent of those 
drug resistant epilepsies.  
The majority of MTLE patients have HS lesions, including astrogliosis, neuronal death 
??????????????????? ????? ?????????? ??????de Lanerolle et al., 2003; Bae et al., 2010; 
Yang et al., 2010). The aberrant sprouting of mossy fibers occurs secondary to neuron 
loss and so, a comprehensive knowledge of this phenomenon will have a key role for 
the development of new treatment options.  
At the present, antiepileptic drugs focus on neuronal targets, mainly glutamatergic and 
GABAergic mechanisms or ion channels. These therapies are largely symptomatic and 
do not affect the underlying disease processes. These drugs often result in deleterious 
side effects including cognitive impairment. Moreover, a large subpopulation of patients 
does not respond to current AEDs, suggesting that there is a great need for new 
therapeutic directions (Wiebe and Jette, 2012).  
Endogenous mechanisms for the termination of seizure activity include the release of 
high enough amounts of ADO, contributing to seizure arrest and postictal 
refractoriness. Because ADO modulates neuronal activity it is considered an 
endogenous anticonvulsant. The activation of ADO inhibitory A1 receptors decreases 
excitatory neurotransmission, and for this reason several ADO-based therapies for 
epilepsy are currently under development. 
Ketogenic diet has been confined to a last resort therapy for refractory epilepsy, 
nevertheless this diet often succeeds in control of seizures when drugs fail. This 
indicates that the metabolic changes produced by the diet tap into anticonvulsant 
mechanisms that are not targeted by existing medication. The diet is unlikely to 




produce treatment resistance and significant untoward side effects (Boison et al., 
2011): One of these mechanisms is the enhancement of ADO levels, leading to a net 
inhibition of excitatory transmission; other proposed mechanisms include disruption of 
glutamatergic synaptic transmission, inhibition of glycolysis, and activation of ATP-
sensitive potassium channels. Follow up studies will show how potent it is the 
antiseizure action of this diet by the integration of individual findings on metabolic 
modification of neuronal activity. 
ADO-dependent changes in DNA methylation were pinpointed as an underlying 
mechanism for the antiepileptogenic properties of ADO therapy. Several targets that 
function by either interacting with DNA or playing a role in gene transcription and 
translation responded to ADO therapy and exhibited a decrease in ???????????????DNA 
methylation. This fact constitutes a benefit since the use of DNA methyltransferase 
(DNMT) inhibitors is associated with complications or side effects (Williams-Karnesky 
et al., 2013). 
Pathologically increased expression of ADK is linked to astrogliosis in many central 
nervous system (CNS) pathologies, leading to reductions in ADO tone and leaving 
neurons more susceptible to damage (Boison, 2008). It has been observed that the 
upregulation of ADK occurs before gross morphological changes in the hippocampus, 
offering a time window for therapeutic intervention (Gouder et al., 2004). 
Consequentely, the use of ADK inhibitors may possibly slow down ???????????? 
deterioration.  
Local administration of ADO in the hippocampus in animal kindling models through icv 
injection markedly attenuated seizures and contributed to postictal refractoriness. 
Systemic administration of selective agonist analogues of the A1 inhibitory ADO 
receptor or selective antagonist analogues of the A2A exitatory ADO receptor 
mimicked ADO icv injection, but the occurrence of intense cardiovascular side effects 
were also observed. Being ADO an ubiquitary molecule, its administration per se (and 
its analogues) leads to numerous adverse effects. Nowadays we find a new era in 
which focal approaches of ADO augmentation are the leading strategies for seizure 
control: Cell- and polymer- based focal ADO augmentation therapies were found to 
provide effective seizure control (Boison, 2009a; Boison & Stewart, 2009); The 
transplantation of ADO releasing stem cells (modified by viral-mediated insertion of 
antisense sequences) potently suppressed kindling epileptogenesis (Li et al., 2007b). 
This viral ADK antisense approach apparently causes permanent reversal of ADK-
based ADO dysregulation in the epileptogenic focus in which ADK levels are 




pathologically high (Boison, 2010a). Yet it is necessary to establish the efficacy of the 
virus in post SE chronic models of epilepsy. 
Polymer-, and in particular silk-based ADO delivery (Wilz et al., 2008; Szybala et al., 
2009), are ideal to start clinical safety and feasibility tests of focal ADO-augmentation. 
Notwithstanding, these systems need to be further improved in order to provide long-
term delivery options for ADO. Furthermore, the translational potential of such studies 
in humans is uncertain.  
Rapamycin has recently received broad attention as a potential broad-spectrum 
effector in seizure suppression and irregular structural modification of the epileptic 
hippocampus (Chong et al., 2010). This drug affects the mammalian target of 
rapamycin (mTOR) protein, which is involved with growth factor production, neuronal 
plasticity and remodeling, glial activation, and cellular motility. As such, it would seem 
that rapamycin has the potential to be a catch-all therapy for MTLE and for epilepsy as 
a whole. Because rapamycin was originally approved as a cancer chemotherapeutic 
(powerfull inhibitor of mitosis and motility of cells) it may not be safe as a long-term 
MTLE treatment. 
New therapeutic targets, which do not include the increase of ADO in the 
hippocampus, have been emerging. Therapies based on the mechanisms now 
evidenced from the study of rapamycin in the hippocampus of rats, in induced 
metabolic changes in neurons by ketogenic diet, and in the mechanisms involved in 
neuro-inflammation, are rapidly developing. However, in the near future, the ADO-














The number of AEDs available for treatment of MTLE are greater than ever, but the 
effectiveness of any AED remains arguably unchanged. Contraindications are better 
managed today but effective seizure-eliminating therapy is not (Löscher and Schmidt, 
2011). 
Much of the mystery of epilepsy is ???? ?? ?????????? ???? ?????? ???????????? ??????
experiments will allow further insites on the interplay among ion channels, cellular 
signaling, neurotransmitter release and reuptake, and inflammatory factors in pre-
epileptic and epileptic tissue. Basic understanding of morphological changes such as 
mossy fiber sprouting, gliosis, and neuron death may lead to identification of specific 
molecules released either as a result of cellular changes or as a prequel to the 
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??????????? ??? lobo mesial temporal: novas abordagens terapêuticas 
????????????- Resumo 
Introdução 
A epilepsia é uma doença neurológica crónica, sendo a mais comum em todo o 
mundo, com cerca de 50 milhões de pessoas afectadas por esta patologia. A epilepsia 
do lobo mesial temporal (MTLE) é a forma de epilepsia parcial mais comum em 
adultos e uma das formas de epilepsia farmacorresistente mais frequentes, sendo 
necessário o recurso à intervenção cirúrgica. A adenosina (ADO) é uma molécula 
sinalizadora extracelular, capaz de coordenar a homeostasia nas células, com efeitos 
de protecção e reparação tecidual. No sistema nervoso tem um papel neuromodulador 
bastante específico, controlando a transmissão e plasticidade sináptica e coordenando 
as redes neuroniais. Esta dupla acção, aliada à evidência de que a ADO actua no 
cérebro como um anticonvulsivante endógeno e que a sua disfunção pode estar 
envolvida no processo epileptogénico, faz da ADO uma molécula cuja compreensão 
dos seus mecanismos de síntese e inactivação permitirá desenvolver estratégias 
terapêuticas que visem a cura desta patologia mais do que o tratamento sintomático.  
Objectivos 
Esta revisão pretende destacar a importância dos mecanismos fisiológicos mediados 
pela ADO na epilepsia, em particular na MTLE. Destina-se a resumir as evidências 
atuais das diversas estratégias terapêuticas emergentes nos últimos anos, que num 
futuro próximo pode dar origem a medicamentos inovadores para o tratamento da 
epilepsia.  
Epilepsia 
A epilepsia é uma desordem cerebral caracterizada pela predisposição para gerar 
crises epilépticas, pelas consequências neurobiológicas, cognitivas, psicológicas e 
sociais desta condição. O diagnóstico de epilepsia é assumido pelos clínicos quando 
decorrem pelo menos duas crises epilépticas não provocadas, embora outros 
considerem apenas uma convulsão, desde que haja uma causa predisponente ou uma 
descarga interictal generalizada sugestiva de predisposição genética. As convulsões 
resultam de descargas excitatórias anormais de neurónios corticais e a sua 
manifestação sintomática depende da localização destas no córtex e da sua medida e 




padrão de propagação no cérebro, sendo altamente variável, mas estereotipada na 
maioria dos doentes. Embora a probabilidade de diagnosticar epilepsia seja cerca de 
3%, a sua prevalência real é próxima de 0,8%. Na maior parte dos casos a causa da 
epilepsia não é conhecida. As causas identificadas variam com a idade do doente, 
sendo os síndromes hereditários mais comuns nas crianças, o traumatismo e o AVC 
em adultos. Os fármacos anti-epilépticos (AED) (ex.: Fenitoína, valproato de sódio, 
carbamazepina) constituem o tratamento de primeira linha para a epilepsia. Os AEDs 
de nova geração (ex.: levetiracetam e lacosamida) têm menores efeitos laterais, 
melhor adaptação mas não alteraram a percentagem de pacientes com epilepsia 
farmacorresistente (~ 30%). Os alvos destes fármacos visam o aumento da 
transmissão inibitória (GABAérgica), a redução da transmissão excitatória 
(glutamatérgica), a modulação da liberação de neurotransmissores e de canais iónicos 
dependentes de voltagem.  
MTLE 
A epilepsia do lobo mesial temporal (MTLE), a forma mais comum de epilepsia 
farmacorresistente, é frequentemente associada a lesões prévias, incluindo traumas, 
convulsões febris, e infecção, levando ao estado epiléptico. Após a lesão inicial, 
decorre um período de latência de 5 a 10 anos sem sintomas ou complicações. 
Quando a atividade convulsiva recomeça a se manifestar, é normalmente controlável 
com medicação (período silencioso), mas no decurso da doença, os sintomas tornam-
se incontroláveis com AEDs comuns. Pensa-se que o período latente envolve 
mudanças estruturais e bioquímicas iniciadas pela lesão primária que conduzem ao 
aparecimento das convulsões. Lesões criadas pela  astrogliose (cicatriz astroglial), 
morte neural e arborização aberrante das fibras musgosas têm sido observados em 
tecido epiléptico humano e animal. As alterações bioquímicas subjacentes 
permanecem obscuras, mas muitos estudos indicam que a convulsão inicial causa 
alterações estruturais primárias que continuam a desenvolver-se no decurso da 
doença. Além das alterações macro-estruturais, muitas alterações bioquímicas e de 
sinalização têm sido descritas, como a sobre-regulação de indicadores inflamatórios 
por aumento de citocinas pro-inflamatórias e fatores de crescimento. A dificuldade da 
hipótese inflamatória é que, apesar da inflamação do cérebro na infância poder 
preceder a epilepsia no adulto, doentes epilépticos que iniciaram a sua patologia já na 
idade adulta também apresentam indicadores inflamatórios no foco epiléptico, não 
relacionados com um episódio inflamatório anterior.  
 






A degeneração neuronial foi uma das primeiras características associadas à MTLE 
reconhecidas, com alterações no hipocampo incluindo diminuição de tamanho, 
endurecimento e perda de neurónios, especialmente nas áreas CA1, CA3 e no hilo 
(CA4) e perda de nerónios extra hipocampais no córtex entorrínico, piriforme e 
amígdala. A importância bem como os mecanismos de degeneração neuronial na 
MTLE permanecem pouco claros.  
Gliose  
A gliose pode revelar-se num aumento de cerca de dez vezes da micróglia ativada. A 
hipótese da cicatriz glial epileptogénica propõe que os astrócitos reativos libertam 
fatores neurotróficos que conduzem à arborização axonial, à formação de sinapses e à 
hiperexcitabilidade. A ativação crónica dos astrócitos aumenta a produção de citocinas 
inflamatórias, potencializa a atividade sináptica excessiva (direta ou indiretamente) e 
induz a migração para o foco epilético, resultando em esclerose. Se estes efeitos são 
a consequência da MTLE ou a causa desta, continua ainda sem resposta. 
Arborização das fibras nervosas 
A arborização é caracterizada por formação de sinapses das células axoniais 
granulosas do dentado com células da camada granular e da camada molecular 
interna sobretudo na região CA3 do corno de Ammon. A ocorrência de gliose, a 
libertação de fatores de crescimento, citocinas, adesões moleculares oriundas da 
ativação de astrócitos e micróglia são alguns dos mecanismos que se assumem estar 
na base deste fenómeno. A hipótese da hiperexcitabilidade defende que as células 
granulosas do dentado se tornam hiperexcitáveis devido à arborização recorrente. 
Outros investigadores afirmam que o aparecimento de células musgosas serve para 
reformular circuitos inibitórios que se perderam durante os danos iniciais nos 
neurónios. O esclarecimento do papel que as fibras musgosas desempenham na 
epileptogénese é importante para a compreensão desta patologia, podendo conduzir a 
novas opções de tratamento.  
Alvos potenciais para o controlo de convulsões 
Pesquisas intensivas estão em curso na tentativa de obter novos AEDs que que visem 
proteínas modulatórias diferentes na transmissão excitatória. Sabendo que a neuro-




inflamação com libertação de inúmeras citocinas e interleucinas estão na base da 
epileptogénese, o desenvolvimento de anti-inflamatórios neuroniais com propriedades 
neuroprotetoras poderá atenuar as alterações decorrentes das convulsões, reduzindo 
assim a doença subjacente. 
Adenosina ? um metabolito retaliatório 
A ADO não é apenas um metabolito do ATP, que reflete o reservatório de energia, 
mas também do RNA, que reflete as atividades metabólicas da célula. Assim, esta 
assume um papel central entre a disponibilidade energética e as exigências 
metabólicas, sendo apelidada ??? ?metabolito retaliatório???????????????para conservar 
energia assenta no aumento da ADO resultante do consumo de ATP, que vai atenuar 
todas as atividades da célula que consomem energia para preservar as reservas de 
ATP. No cérebro, as convulsões provocam uma queda rápida de energia, resultando 
no aumento dos níveis de ADO até cerca de 40 vezes. A ADO vai atuar como um 
terminador endógeno das convulsões, assim como induzir um ambiente de depressão 
pós-convulsiva que impede a propagação dos estímulos a partir do foco epiléptico. A 
supressão das convulsões pela ADO depende da ativação dos recetores inibitórios de 
adenosina A1 (A1R), acoplados à proteína G. Evidências recentes sugerem que a 
ADO  intervem numa série de funções importantes de regulação independentes dos 
seus receptores, nomeadamente interações com a bioenergética mitocondrial, 
interferência com reações enzimáticas e nas funções epigenéticas. Assim sendo, a 
ADO, assume um papel único enquanto regulador da homeostasia. 
Vias dependentes do receptor de adenosina 
Um vasto conjunto de mecanismos produzidos pela ADO é mediado pela interacção 
com recetores purinérgicos específicos, da família P1, que se distinguem da família de 
recetores purinérgicos sensíveis ao ATP, da família P2. Existem 4 membros da classe 
P1: A1R, A2AR, A2BR e A3R. Cada recetor apresenta uma farmacologia distinta e tem 
uma distribuição particular nos tecidos e sub-tipos celulares: Ao nível do cérebro os 
A1R são expressos principalmente, no sistema límbico, os A2AR nos núcleos da base 
e os A2BR e A3R principalmente na periferia. Os A1R localizados pré-sinapticamente 
inibem a libertação sináptica da maioria dos neurotransmissores, com um efeito 
aparentemente maior na transmissão excitatória. No componente pós-sináptico, os 
A1R hiperpolarizam as membranas através da abertura dos canais retificadores de 
potássio, sensíveis ao ATP. Estes dois efeitos combinados da ADO e dos seus 
agonistas selectivos para os A1R, contribuem para a inibição da excitabilidade da rede 
sináptica, exercendo um efeito anti-convulsivante marcado. O efeito que resulta da 




activação dos A2AR na excitabilidade neuronial é menos evidente, e anatomicamente 
restrito. Assim, os A1R e A2AR podem cooperar para promover a homeostasia. 
Bioenergética mitocondrial 
O mecanismo da ADO na manutenção da homeostasia do neurónio deve-se à sua 
interação direta com a bioenergética mitocondrial e com o metabolismo energético, 
através do ciclo Adenosina-AMP. Assim sendo, a reposição da bioenergética 
mitocondrial pela ADO tem o potencial de oferecer o duplo benefício de melhorar a 
disfunção metabólica e restaurar a homeostasia neuronial. 
Dieta Cetogénica 
Desde 1920, a dieta cetogénica é utilizada para tratar doentes (principalmente 
crianças) com epilepsia refractária aos AEDs. A sua composição é maioritariamente à 
base de lípidos com pequenas quantidades de hidratos de carbono e de proteínas. A 
elevada oxidação dos ácidos gordos gera grandes concentrações de Acetil-CoA e 
consequente síntese de corpos cetónicos, que passam a ser utilizados como principal 
fonte de energia para os tecidos. Os corpos cetónicos têm um papel anti-convulsivante 
importante: reduzem a excitabilidade neuronial ao diminuir a secreção de glutamato; 
aumentam a transmissão inibitória ao aumentar a produção de GABA; reduzem a 
expressão do factor neurotrófico BDNF e do seu receptor TrkB (ambos relacionados 
com a epileptogénese) ao reduzir a glicólise; levam à mobilização de ATP mitocondrial 
que vai por sua vez activar canais de potássio sensíveis ao ATP (KATP) 
hiperpolarizando os neurónios pós-sinapticos. A metabolização deste ATP mitocondrial 
aumenta também os níveis de ADO extracelulares, que por sua vez vai reduzir ainda 
mais a excitabilidade neuronial ao activar os A1R pré e pós-sinápticos. A ADO vai 
inibir pré-sinapticamente o influxo de cálcio e vai activar pós-sinapticamente os canais 
rectificadores de K+, potenciando a hiperpolarização induzida pelo ATP nos neurónios 
pós-sinápticos. Este aumento nos níveis de adenosina extracelular desempenha um 
papel fundamental no sucesso terapêutico da dieta cetogénica.  
Hipotese da metilação do DNA 
Há uma série de doenças neurológicas relacionadas com a epilepsia que são 
diretamente atribuídas a mutações genéticas primárias, resultando na 
desregulamentação secundária do epigenoma. O que se observa nos tecidos 
excisados de pacientes com MTLE são promotores de genes com padrões de 
hipermetilação do DNA e com expressão diminuída do gene da DNA 




metiltransfererase. Os mecanismos subjacentes ao aumento da metilação do DNA na 
epileptogénese não estão bem caraterizados e são alvo de grande especulação. A 
hipótese epigenética sugere que a mudança gradual no rácio de desmetilação e 
metilação de novo do DNA, desencadeada por uma lesão precipante e modificada por 
fatores intrínsecos e ambientais, conduz ao aumento da metilação, expressão alterada 
de genes e um fenótipo alterado (ex: convulsão). Enquanto produto obrigatório da 
transmetilação, a ADO exerce um efeito tónico sobre a via de transmetilação 
regulando a disponibilidade do substrato e consequentemente a homeostasia do 
metiloma do DNA. A astrogliose e a sobre-expressão da ADK no hipocampo, ao 
reduzirem os níveis tónicos de ADO, podem contribuir para a epileptogénese através 
da manutenção de um estado hipermetilado do DNA do hipocampo. 
Desequilibrio da Adenosina cinase no cérebro 
Os astrócitos constituem a via principal de recaptação da ADO, controlando a sua 
disponibilidade extracelular através do balanceamento da expressão da enzima 
astrocitária ADK. Esta enzima ao converter a ADO em AMP, promove o seu influxo 
para o astrócito, através de transportadores equilibrativos. Lesões no cérebro 
desencadeiam um aumento agudo de ADO e a regulação negativa transitória de ADK. 
A lesão inicial e o aumento associado de ADO podem induzir a expressão de A2AR 
nas células da glia e que estão implicados na proliferação e ativação de astrócitos. A 
astrogliose é um achado típico patológico que tem sido consistentemente associado à 
sobre-expressão da ADK, responsável pelos níveis reduzidos de ADO.  
Aumento focal de adenosina 
O aumento sistémico dos níveis de ADO ou dos seus agonistas selectivos não é uma 
opção terapêutica devido aos seus efeitos secundários generalizados, principalmente 
cardiovasculares. Do mesmo modo o recurso a inibidores da ADK não é opção devido 
à toxicidade hepática destes compostos. O aumento focal no hipocampo de ADO pode 
ultrapassar todos os efeitos secundários decorrentes da sua administração sistémica, 
repondo a sua homeostasia no foco epiléptico. As pesquisas que visam a obtenção de 
dispositivos de libertação local de ADO no hipocampo epiléptico estão em franco 
desenvolvimento.  
Os primeiros implantes testados eram feitos com membranas semipermeáveis que 
libertavam doses controladas de ADO no hipocampo. Posteriormente foram feitos 
implantes com membrana de seda (menos imunogénica) contendo células-tronco 
embrionárias, manipuladas para libertar ADO. Estes implantes controlaram por 




completo as convulsões nos ratos epilépticos, efeito esse de curta duração, devido às 
quantidades limitadas de ADO ou ao tempo de vida curto das células nos dispositivos. 
Novos dispositivos contendo células-tronco, com sequências anti-sense contra o gene 
adk, foram testados. Três semanas depois da sua implantação registou-se uma 
atenuação marcada da astrogliose, a normalização dos níveis de ADK e a ausência 
total de crises nos hipocampos dos ratos epilépticos, sugerindo uma regulação 
persistente dos níveis de ADO. Estes dados são promissores uma vez que só o 
restabelecimento definitivo dos níveis de ADO no hipocampo por estes dispositivos 
poderá ser viável terapeuticamente. 
Discussão 
Ao longo das últimas décadas, muitos estudos têm tentado identificar as alterações 
morfológicas e bioquímicas que perpetuam a progressão da epilepsia até um estado 
refratário, resistente ao controlo por AEDs. A MTLE é a epilepsia farmacorresistente 
mais frequente, e a maioria dos doentes com MTLE apresenta lesões escleróticas 
hipocampais, incluindo astrogliose, morte neuronal e arborização aberrante das fibras 
musgosas. O esclarecimento destes achados histológicos é um passo importante na 
melhor compreensão da epileptogénese, e de novas opções de tratamento. 
Os AEDs disponíveis visam o tratamento sintomático, não se registando quaisquer 
modificações nos processos subjacentes da epilepsia. Apesar dos AEDs de terceira 
geração causarem menos efeitos adversos, não conseguem tratar ainda a grande sub-
população de doentes com epilepsia farmacorresistente, o que implica desenvolver 
opções terapêuticas inovadoras. A ADO modula a atividade neuronal, sendo 
considerada um anti-convulsionante endógeno por diminuir a transmissão excitatória. 
Tendo em conta essa evidência, novas terapias baseadas na ADO estão atualmente a 
ser desenvolvidas. 
O uso da dieta cétogénica tem sido sucesso no controlo de crises epilépticas 
(sobretudo em crianças) quando os AEDs falham. As alterações metabólicas por ela 
produzidas ativam mecanismos anticonvulsivos diferentes dos alvos visados pela 
medicação existente. O aumento dos níveis de ADO é um dos principais mecanismos 
anticonvulsivos activados, contribuindo para uma inibição global da transmissão 
excitatória. Outras alterações metabólicas identificadas, contribuem para o potente 
efeito anti-convulsivo produzido por esta dieta.  
Mudanças na metilação do DNA no hipocampo induzidas pela ADO foram apontadas 
como um dos mecanismos subjacentes às propriedades anti-epileptogénicas desta 




molécula. A redução da metilação do DNA hipermetilado em hipocampos de ratos 
epilépticos pela ADO constitui um benefício, uma vez que o uso de inibidores da DNA 
metiltransferase (DNMT) na redução das crises convulsivas, está associado a vários 
efeitos adversos. 
O aumento patológico de ADK, decorrente da astrogliose, reduz os níveis tónicos de 
ADO, deixando os neurónios mais susceptíveis a danos. Sabendo que a sobre-
regulação da ADK ocorre antes da ocorrência de modificações morfológicas 
significativas no hipocampo, há um período de tempo em que é possível modificar esta 
sobre-expressão, recorrendo ao uso de inibidores da ADK como agentes  terapêuticos.    
A administração sistémica de ADO ou dos seus agonistas estáveis para o controlo das 
crises epilépticas é impraticável devido aos numerosos efeitos adversos, 
maioritariamente no sistema cardiovascular. Uma nova era de pesquisa de técnicas 
que aumentem focalmente a ADO está em franca expansão. Dispositivos que libertam 
ADO, contendo polímeros de libertação controlada ou células histaminais manipuladas 
geneticamente, controlaram as crises em modelos de rato epiléptico. Células 
histaminais contendo sequências  anti-sense contra o gene adk, incorporadas em 
implantes de seda, reverteram de forma definitiva a desregulação da ADK, reduziram a 
astrogliose e cessaram completamente as crises nos ratos epilépticos.  
Apesar dos dispositivos de libertação de ADO serem neste momento os mais 
plausíveis para testes clínicos de segurança e viabilidade, estes sistemas necessitam 
de ser melhorados para fazerem libertação de ADO durante períodos prolongados. 
Além disso, ainda é incerto a translação dos estudos feitos em modelos animais para o 
homem.  
Conclusões 
Tem-se verificado um vasto aumento do número de AEDs disponíveis para o 
tratamento da MTLE, mas a sua eficácia no tratamento e possível cura mantêm-se 
inalterada. Novas experiências irão permitir esclarecer melhor a forma como interagem 
os canais iónicos com a sinalização celular, a libertação de neurotransmissores e os 
fatores inflamatórios em tecidos epilépticos e pré-epilépticos. A compreensão das 
alterações morfológicas como a arborização das fibras musgosas, gliose e morte dos 
neurónios pode levar à identificação de moléculas específicas libertadas como 
resultado de alterações celulares ou como precursoras das mudanças e que poderão 
ser bons alvos para futuras abordagens terapêuticas. 
